Inhibrx Biosciences Reports Positive Registrational Data for Ozekibart, Plans Q2 2026 BLA Submission, and Secures $75M in Additional Debt

summarizeSummary

Inhibrx Biosciences' annual report highlights positive registrational trial results for ozekibart in chondrosarcoma, with a Biologics License Application planned for early Q2 2026, alongside successful additional debt financing of $75 million to bolster liquidity.

check_boxKey Events

• Ozekibart Registrational Trial Success

  Positive data from the registrational trial for ozekibart (INBRX-109) in advanced or metastatic chondrosarcoma, showing a 52% reduction in disease progression or death and doubling median progression-free survival.

• Planned BLA Submission

  The company plans to submit a Biologics License Application (BLA) for ozekibart in chondrosarcoma to the FDA early in the second quarter of 2026.

• Additional Debt Financing Secured

  Secured an additional $75.0 million in Term B Loans from Oxford Finance LLC on March 18, 2026, increasing total debt to $175.0 million and extending the liquidity runway.

• Pipeline Advancement

  Reported positive interim Phase 1/2 data for ozekibart in Ewing Sarcoma and colorectal adenocarcinoma, with plans to discuss accelerated approval pathways with the FDA in H2 2026 for both indications.

auto_awesomeAnalysis

The 10-K filing from Inhibrx Biosciences, Inc. is highly significant due to the positive registrational trial results for its lead therapeutic candidate, ozekibart (INBRX-109), in chondrosarcoma. The achievement of the primary endpoint, demonstrating a 52% reduction in the risk of disease progression or death and a doubling of median progression-free survival, is a major de-risking event for the company and paves the way for a Biologics License Application (BLA) submission to the FDA in early Q2 2026. This represents a critical step towards potential commercialization in a disease with no approved systemic options.

Further bolstering the company's outlook, Inhibrx reported positive interim Phase 1/2 data for ozekibart in Ewing Sarcoma and colorectal adenocarcinoma, with discussions for accelerated approval pathways anticipated in the second half of 2026. The advancement of INBRX-106, with Phase 2 enrollment completed in Q1 2026 and upcoming data readouts, indicates broad pipeline progress.

Financially, the company secured an additional $75.0 million in Term B Loans on March 18, 2026, increasing its total debt to $175.0 million. This financing, while adding to debt, is crucial for extending the company's liquidity runway, which is now projected to be sufficient for at least the next 12 months. The issuance of warrants in connection with this debt is a minor dilutive factor compared to the capital secured. The overall sentiment is positive, reflecting substantial clinical progress and strengthened financial position to advance its oncology pipeline.